Panel Discussion: Is Plaque Reduction a Valid Marker of Response & Sufficiently Relevant to Drug Efficacy?
Time: 9:00 am
day: Conference Day One
Details:
- Navigating how the recent approval of amyloid clearing antibody drugs will affect regulator perception of plaque reduction as a marker of drug efficacy
- Reviewing if plaque targeting is relevant for drugs with a different mechanism of action and if this affects the safety profile too significantly
- Exploring the relevance of plaque clearance in heterogenous pathology of Alzheimer’s disease with varying biological basis
- Discussing alternative clinically relevant markers of drug efficacy and the route required to validate them
